PHASE I EVALUATION OF A MODIFIED HEPATIC ARTERY INFUSION CATHETER

该方案的目的是检查阿司匹林的疗效和毒性 动脉内注射FUDR和口服亚叶酸钙 改良肝动脉导管联合系统 5-氟尿嘧啶(5FU)和α-干扰素在患者中的应用 结肠癌转移到肝脏。动脉内输注 使用标准输液导管的FUDR有效率很高，但 与显著的肝脏毒性有关。主要并发症 动脉内输注的是意外的肝外分娩 化疗、化学性肝炎、化学性胆囊炎和 胆道硬化症的潜在致命并发症。一种改良的肝脏 动脉导管已经被开发出来，其结果是产生湍流 导管顶端气球的充气。肝气球 动脉导管会产生湍流并使输液混合 并可能预防与目前的 用了导尿管。转移性结肠癌的肝外进展 是与肝动脉灌注治疗有关的另一个问题。一个 5-氟尿嘧啶和α-氟尿嘧啶组成的非常有效的化疗免疫方案 干扰素将与动脉内FUDR联合使用，试图 控制肝外转移疾病。

The purpose of this protocol is to examine the efficacy and toxicity of intraarterial fluorogeoxyuridine (FUDR) and oral leucovorin using a modified hepatic artery catheter in combination with system administration of 5-fluorouracil (5FU) and alpha interferon for patients with colon cancer metastatic to the liver. Intraarterial infusion of FUDR using standard infusion catheters produces a high response rate but is associated with significant hepatic toxicity. The major complications of intraarterial infusion are accidental extra-hepatic delivery of chemotherapy, chemical hepatitis, chemical cholecystitis and a potentially lethal complication of biliary sclerosis. A modified hepatic artery catheter has been developed that produces turbulence as a result of the inflation of a balloon at the catheter tip. The balloon hepatic artery catheter produces turbulence and allows mixing of the infusate with blood and may prevent complications associated with the currently employed catheters. Extrahepatic progression of metastatic colon cancer is the other problem associated with hepatic artery infusion therapy. A very effective chemoimmunotherapy regimen consisting of 5FU and alpha interferon will be combined with intra-arterial FUDR in an attempt to control metastatic disease outside of the liver.